Desmoteplase for acute ischaemic stroke - horizon scanning review
NHSC
Record ID 32005000241
English
Authors' objectives:
This study aims to assess the effectiveness of desmoteplase for acute ischaemic stroke.
Authors' recommendations:
Desmoteplase is a recombinant fibrin-specific plasminogen activator that is in the planning stages of phase III clinical trials for patients with acute ischaemic stroke within 3-9 hours after symptom onset. Patients need a diffusion/perfusion MRI or perfusion CT prior to therapy. Desmoteplase is administered intravenously as a bolus dose of 90mcg/kg or 125mcg/kg. If successful in trials and licensed desmoteplase would extend the time window for thrombolysis in acute stroke from 3 hours to 9 hours. Two small randomised phase II trials suggest an increase in favourable 90-day patient outcomes from 25% with placebo to 60% for desmoteplase 125mcg/kg.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Acute Disease
- Brain Ischemia
- Plasminogen Activators
- Stroke
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.